A first-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers

Authors
Category Primary study
JournalJournal of Clinical Oncology
Year 2016
This article has no abstract
Epistemonikos ID: ab7245de5b6830623fc9295dbafd6bb543a10daa
First added on: Feb 07, 2025